-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx Announces Results From Clinical Study Demonstrating High Accuracy Of Nu.Q Vet Feline Assay In Detecting Lymphoma In Cats

Benzinga·01/08/2026 13:47:11
Listen to the news

Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection

HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.